|
Date: 11 Mar 2021
Time: 11am - 12pm Topic: Panel discussion "Immune Cell Therapy Roundtable" Format: Zoom Meeting (registration is required) Hosted by: Adrian Teo, IMCB & ExCo SCSS Alvin Soetedjo, IMCB |
Panelists' information
|
Jacqueline NG
Thermo Fisher Scientific Investing in cell and gene therapy partnerships and development |
|
Abstract
Cell and gene therapy manufacturers are transforming lives by making better therapies more accessible. As the world leader in serving science, Thermo Fisher Scientific is uniquely positioned to provide the high-quality materials, services and support needed to accelerate the pace of advanced therapy development. Jacqueline will give an industry perspective on investments made to address existing technological and service gaps in the field. This ranges from acquisitions of viral vector manufacturing capabilities to the expansion of critical raw material manufacturing facilities. She will also speak about recent industry partnerships that allowed existing cell and gene therapy developers to access novel technologies.
Bio
Jacqueline Ng is the Regional Manager responsible for Thermo Fisher Scientific's cell and gene therapy business in the Asia Pacific. Her team is currently involved in supporting researchers, biotech and biopharma companies across the region, with a focus on those that are developing therapies with the Gibco™️ Cell Therapy System (CTS™️) and other related ancillary reagents and instruments. Over the years, she has developed expertise in providing commercial and technical support to translational researchers and the cell and gene therapy community. Prior to her current role, Jacqueline spent a decade with STEMCELL Technologies Inc, building up its business in Singapore and ASEAN. She began her career formulating public healthcare policies at the Ministry of Health (Singapore), and obtained her MSc in Management (Health Industries) at ESSEC business school and BSc (Hons) at the University of Melbourne.
Cell and gene therapy manufacturers are transforming lives by making better therapies more accessible. As the world leader in serving science, Thermo Fisher Scientific is uniquely positioned to provide the high-quality materials, services and support needed to accelerate the pace of advanced therapy development. Jacqueline will give an industry perspective on investments made to address existing technological and service gaps in the field. This ranges from acquisitions of viral vector manufacturing capabilities to the expansion of critical raw material manufacturing facilities. She will also speak about recent industry partnerships that allowed existing cell and gene therapy developers to access novel technologies.
Bio
Jacqueline Ng is the Regional Manager responsible for Thermo Fisher Scientific's cell and gene therapy business in the Asia Pacific. Her team is currently involved in supporting researchers, biotech and biopharma companies across the region, with a focus on those that are developing therapies with the Gibco™️ Cell Therapy System (CTS™️) and other related ancillary reagents and instruments. Over the years, she has developed expertise in providing commercial and technical support to translational researchers and the cell and gene therapy community. Prior to her current role, Jacqueline spent a decade with STEMCELL Technologies Inc, building up its business in Singapore and ASEAN. She began her career formulating public healthcare policies at the Ministry of Health (Singapore), and obtained her MSc in Management (Health Industries) at ESSEC business school and BSc (Hons) at the University of Melbourne.
|
Teck Guan SOH
ACTRIS Support of Local Cell and Gene Therapy Ecosystem with the Setting up of a National Cell and Gene Therapy Programme – Advanced Cell Therapy and Research Institute, Singapore (ACTRIS) |
|
Abstract
The Advanced Cell Therapy and Research Institute, Singapore (ACTRIS) was established on 20 April 2020 to meet the increasing clinical demand of using cellular therapeutics to treat various life-threatening diseases. ACTRIS’s vision is to be the national and regional Centre of Excellence for discovery, process development and manufacturing of cellular-based therapeutics across the broad spectrum of immunotherapy and regenerative medicine, encompassing both investigational and approval products for the local market. ACTRIS aims to achieve accreditation from national and international regulators to ensure quality compliance of resource-efficient cellular therapy manufacturing. Our common goal is to promote and foster the entire value chain of the cellular therapy ecosystem through enabling translational research and development, manufacturing, clinical service provision and commercialisation by serving the healthcare, academic and industrial sectors. ACTRIS will also provide value-added services such as workforce training, regulatory facilitation and ancillary material standardization pertaining to delivery of cellular therapy to patients.
Bio
Education
BSc. in Life Science (Molecular Cell Biology) from National University of Singapore
MSc in Transfusion and Transplantation from University of Bristol, UK.
Experience
Facility Supervisor in Stem Cell Laboratory, National University Hospital (NUH) since 2005. Has supported the facility to obtain international accreditations – Foundation for Accreditation of Cell Therapy (FACT) for Haematopoietic Cellular Therapy, AABB for Cellular Therapy and College of American Pathologist (CAP).
Laboratory Manager of TECT Laboratory, NUH since 2016 as Laboratory Manager. Has support the facility to obtain international accreditation – FACT for Immune Effector Cell.
Previously the Quality Manager of NUHS HPCT Programme. Assisted the Programme to setup the Quality Management System. Stood down from this position in 2019.
Processing Lab Inspector for FACT since 2012.
Member of the MOH Stem Cell Transplant Working Committee
Senior Project Administrator under the PTP Scheme of MOH in Advanced Cell Therapy and Research Institute, Singapore (ACTRIS) Implementation Office.
The Advanced Cell Therapy and Research Institute, Singapore (ACTRIS) was established on 20 April 2020 to meet the increasing clinical demand of using cellular therapeutics to treat various life-threatening diseases. ACTRIS’s vision is to be the national and regional Centre of Excellence for discovery, process development and manufacturing of cellular-based therapeutics across the broad spectrum of immunotherapy and regenerative medicine, encompassing both investigational and approval products for the local market. ACTRIS aims to achieve accreditation from national and international regulators to ensure quality compliance of resource-efficient cellular therapy manufacturing. Our common goal is to promote and foster the entire value chain of the cellular therapy ecosystem through enabling translational research and development, manufacturing, clinical service provision and commercialisation by serving the healthcare, academic and industrial sectors. ACTRIS will also provide value-added services such as workforce training, regulatory facilitation and ancillary material standardization pertaining to delivery of cellular therapy to patients.
Bio
Education
BSc. in Life Science (Molecular Cell Biology) from National University of Singapore
MSc in Transfusion and Transplantation from University of Bristol, UK.
Experience
Facility Supervisor in Stem Cell Laboratory, National University Hospital (NUH) since 2005. Has supported the facility to obtain international accreditations – Foundation for Accreditation of Cell Therapy (FACT) for Haematopoietic Cellular Therapy, AABB for Cellular Therapy and College of American Pathologist (CAP).
Laboratory Manager of TECT Laboratory, NUH since 2016 as Laboratory Manager. Has support the facility to obtain international accreditation – FACT for Immune Effector Cell.
Previously the Quality Manager of NUHS HPCT Programme. Assisted the Programme to setup the Quality Management System. Stood down from this position in 2019.
Processing Lab Inspector for FACT since 2012.
Member of the MOH Stem Cell Transplant Working Committee
Senior Project Administrator under the PTP Scheme of MOH in Advanced Cell Therapy and Research Institute, Singapore (ACTRIS) Implementation Office.
|
Wee Kiat Tan
CytoMed Therapeutics |
|
BIO
Wee Kiat Tan served as Chief Operating Officer of CytoMed Therapeutics where he oversees the GMP facility, manufacturing and quality systems Prior to joining CytoMed Therapeutics, he served as a research scientist in another biotech company and was responsible for process-mapping and development for cell-based immunotherapy. He received his Ph. D from National University of Singapore (NUS) before starting his biomedical research in 2016. During his undergraduate and graduate studies, his research focused on cell based cancer immunotherapeutics using a wide variety of immune cells including Natural Killer cells, gamma delta γδ T cells, dendritic cells and CAR-γδ T cells.
Wee Kiat Tan served as Chief Operating Officer of CytoMed Therapeutics where he oversees the GMP facility, manufacturing and quality systems Prior to joining CytoMed Therapeutics, he served as a research scientist in another biotech company and was responsible for process-mapping and development for cell-based immunotherapy. He received his Ph. D from National University of Singapore (NUS) before starting his biomedical research in 2016. During his undergraduate and graduate studies, his research focused on cell based cancer immunotherapeutics using a wide variety of immune cells including Natural Killer cells, gamma delta γδ T cells, dendritic cells and CAR-γδ T cells.
Yannick Simoni
ImmunoScape
Illuminating the Immune Landscape
ImmunoScape
Illuminating the Immune Landscape
Abstract
ImmunoScape intends to transform the development of next-generation immunotherapies by providing deep Immunological Insights in clinical trials. Tumor-specific CD8+ T cells are the key immune cells which mediate immunotherapy biological activity by killing tumor cells. Measuring T cell specificity and function is paramount to generate predictive biomarkers of successful therapy and to stratify patients who are likely to respond to treatment. ImmunoScape has developed new methods for revealing both T cell phenotype and antigen specificity at unprecedented resolution. ImmunoScape’s single cell approaches combines in-depth phenotypic analysis with assessment of antigen-specific T cell responses across an extensive range of epitopes, supporting a deep understanding of the patient’s immune response to cancer. Our powerful Immune Profiling and Bioinformatics Tools provide Key Benefits in: 1- Cell Therapies, 2- Antibodies based targeted therapeutics, 3- Vaccines, 4- Neoantigens discovery.
ImmunoScape intends to transform the development of next-generation immunotherapies by providing deep Immunological Insights in clinical trials. Tumor-specific CD8+ T cells are the key immune cells which mediate immunotherapy biological activity by killing tumor cells. Measuring T cell specificity and function is paramount to generate predictive biomarkers of successful therapy and to stratify patients who are likely to respond to treatment. ImmunoScape has developed new methods for revealing both T cell phenotype and antigen specificity at unprecedented resolution. ImmunoScape’s single cell approaches combines in-depth phenotypic analysis with assessment of antigen-specific T cell responses across an extensive range of epitopes, supporting a deep understanding of the patient’s immune response to cancer. Our powerful Immune Profiling and Bioinformatics Tools provide Key Benefits in: 1- Cell Therapies, 2- Antibodies based targeted therapeutics, 3- Vaccines, 4- Neoantigens discovery.